A phase II trial of recombinant MAGE-A3 protein with immunostimulant AS15 in combination with high-dose Interleukin-2 (HDIL2) induction therapy in metastatic melanoma
Details
The content you want is available to Zendy users.Already have an account? Click here. to sign in.